<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693650</url>
  </required_header>
  <id_info>
    <org_study_id>P20002</org_study_id>
    <nct_id>NCT04693650</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-site, Randomized, Sham-Controlled, Double-Blind Trial With One-Way Crossover Designed to Assess the Effectiveness and Safety of the Gimer NeuroBlock SCS Trialing System for the Treatment of Chronic Back Pain and/or Lower Limb Pain</brief_title>
  <official_title>A Prospective, Multi-site, Randomized, Sham-Controlled, Double-Blind Trial With One-Way Crossover Designed to Assess the Effectiveness and Safety of the Gimer NeuroBlock SCS Trialing System for the Treatment of Chronic Back Pain and/or Lower Limb Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GiMer Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GiMer Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multi-site, randomized, shamcontrolled, double-blind trial with&#xD;
      one-way crossover designed to assess the effectiveness and safety of the Gimer NeuroBlock SCS&#xD;
      Trialing System for the treatment of chronic back pain and/or lower limb pain. The NeuroBlock&#xD;
      SCS Trialing System is an ultra-high frequency SCS device for the treatment of patients with&#xD;
      chronic back pain and/or lower limb pain who are refractory to conservative pain management.&#xD;
      After screening procedures, eligible subjects will enter the study which is comprised of a&#xD;
      1-week randomized testing period, a 1-week follow-up period and 2-week observation period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness: Responder Rate</measure>
    <time_frame>2 weeks</time_frame>
    <description>The responder rate of the test group and control group at the 2-week visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: AEs and SAEs</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence of adverse events (AEs) and serious AEs (SAEs)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Low Back Pain</condition>
  <condition>Lower Limb Pain</condition>
  <arm_group>
    <arm_group_label>Treatment group- UHF(+RF) stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients implanted with leads and be administered with UHF stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients implanted with lead receiving fake stimulation (no stimulation but same device procedure with test group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroBlock UHF stimulation</intervention_name>
    <description>NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse</description>
    <arm_group_label>Treatment group- UHF(+RF) stimulation</arm_group_label>
    <other_name>+RF (plus RF, pulsed RF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 20&#xD;
&#xD;
          2. Subject has been diagnosed with chronic, intractable pain of the trunk and/or limb(s)&#xD;
             and is refractory to conservative therapy for a minimum of six months prior to the&#xD;
             screening/baseline visit.&#xD;
&#xD;
          3. Subject has an average pain score of back or leg ≥ 5 or maximum pain score of back or&#xD;
             leg ≥ 7 on the Visual Analogue Scale (VAS).&#xD;
&#xD;
          4. Subject is willing and able to comply with the procedure and requirements of this&#xD;
             trial.&#xD;
&#xD;
          5. The subject is able to understand and provide informed consent, and has signed their&#xD;
             written informed consent in accordance with IRB requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has the following conditions by investigator's discretion at screening visit&#xD;
             or during the last 3 months:&#xD;
&#xD;
               1. has the mental or psychological condition that affects pain perception or&#xD;
&#xD;
               2. has difficulty performing objective pain assessment or lack of suitability for&#xD;
                  participation in the study.&#xD;
&#xD;
          2. Subject has exhibited unstable pain condition within the past 28 days as interviewed&#xD;
             by Investigator.&#xD;
&#xD;
          3. Subject has a currently diagnosed coagulation disorder, bleeding diathesis,&#xD;
             progressive peripheral vascular disease with PLT &lt; 100,000/μl or INR &gt; 1.4 at&#xD;
             screening visit.&#xD;
&#xD;
          4. Subject has unstable pain medication(s) for at least 28 days at investigator's&#xD;
             discretion.&#xD;
&#xD;
          5. Subject currently has an active implantable device including ICD, pacemaker, spinal&#xD;
             cord stimulator or intrathecal drug pump or subject requires magnetic resonance&#xD;
             imaging (MRIs) or diathermy.&#xD;
&#xD;
          6. Subject has a current diagnosis of cancer with active symptoms.&#xD;
&#xD;
          7. Subject has a known terminal illness with life expectancy less than one year.&#xD;
&#xD;
          8. Subject has a systematic or local infection, which may increase study risk.&#xD;
&#xD;
          9. Subject currently has an indwelling device that may pose an increased risk of&#xD;
             infection.&#xD;
&#xD;
         10. Subject is pregnant or breast feeding.&#xD;
&#xD;
         11. Subject has a medical history of drug or alcohol addiction within the past 2 years.&#xD;
&#xD;
         12. Subject has participation in any investigational study in the last 30 days or current&#xD;
             enrollment in any trial.&#xD;
&#xD;
         13. Subject is currently involved in an injury claim law suit or medically related&#xD;
             litigation, including workers compensation.&#xD;
&#xD;
         14. Subject is a prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Max Huang</last_name>
    <phone>+886 2 2697 2680</phone>
    <phone_ext>302</phone_ext>
    <email>max@gimermed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tina Chang</last_name>
    <email>tina@gimermed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Yu-Cheng Liu</last_name>
      <phone>+886 975-681575</phone>
      <email>liuyc1103@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yu-Cheng Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chia-Shiang Lin</last_name>
      <phone>+886 975-835522</phone>
      <email>seancslin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chia-Shiang Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chih-Peng Lin</last_name>
      <phone>+886 972-651804</phone>
      <email>cplin0123@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chih-Peng Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital-Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Cheng-Chia Lee</last_name>
      <phone>+886 938-592570</phone>
      <email>cclee12@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Cheng-Chia Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

